Skip to main content
Innovations Inspired by
life
Search
Menu
Search
Hamburger
Our Company
Who we are
History
Culture
Board of Directors
Leadership Team
OUR RESEARCH
Therapeutic focus
Delivery Technologies
Research Programs
R&D Pipeline
Our Medicines
Xelpros™
Business Development
Strategy
Partner with us
Investors
Financials
Annual reports
Presentations
Chairman's Speech
Committees of Board of Directors
Shareholding pattern
Announcements & Disclosures
Policies & Codes
Listing Information
FAQ’s
Investors Contact
Go green
Media
Press Releases
Presentations
Careers
Overview
Apply Now
Contact Us
Investors
»
Announcements & Disclosures
Investors
Financials
Annual reports
Presentations
Chairman's Speech
Committees of BOD's
Shareholding pattern
Announcements & Disclosures
Policies & Codes
Listing Information
FAQ’s
Investors Contact
Go green
Announcements & Disclosures
Achievement of milestone – Commercialisation of XELPROS™
Download
Allotment of 6060606 equity shares on conversion of warrants
Download
Receipt of US FDA Approval of ELEPSIA(tm) XR 1000mg and ELEPSIA(tm) XR 1500mg
Download
Inter-se change in the shareholding of certain promoter group entities on account of Scheme of Amalgamation
Download
Notice of Board Meeting on 29th October 2018
Download
Allotment of 50,50,505 equity shares on conversion of Warrants
Download
Voting Results – 13th Annual General Meeting
Download
Proceedings of 13th Annual General Meeting
Download
Notice of Board Meeting on 30th July 2018
Download
Revised Articles of Association proposed for shareholders approval at 13th AGM
Download
Pagination
Current page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
Next ›
Last page
Last »
